爱博医疗表示，公司根据市场变化，对隐形眼镜业务相关商誉及部分固定资产计提了资产减值，叠加隐 形眼镜渠道建设投入、销售费用增加较多，导致本报告期净利润同比出现较大幅度下降。 （文章来源：北京商报） 北京商报讯2月27日晚间，爱博医疗（688050）发布2025年度业绩快报显示，报告期内，公司实现营业 收入14.83亿元，同比增长5.15%；归属净利润2.65亿元，同比下降31.67%。 ...

证券日报网讯2月27日，爱博医疗在互动平台回答投资者提问时表示，公司与银河通用已签订正式合作 协议，聚焦具身智能技术与医疗健康零售场景的深度融合，共同打造24小时隐形眼镜智慧门店，探索智 能化医疗零售新模式。 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2026-003 1、主营业务状况 爱博诺德（北京）医疗科技股份有限公司 2025 年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"） 2025 年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公 司 2025 年年度报告为准，敬请投资者注意投资风险。 一、2025 年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 148,270.27 | 141,002.25 | 5.15 | | 营业利润 | 28,993.91 | 43,300.06 | -33.04 | | 利润总额 | 28,952.14 | 43,110.01 | -32.84 | | 归属于母公司所有者的净利润 | 26,541.48 | 38,840.29 | -31.67 | | 归属于母公司所有者 ...

爱博医疗公告，2025年度实现营业总收入14.83亿元，同比增长5.15%；净利润为2.65亿元，同比下降 31.67%。公司根据市场变化，对隐形眼镜业务相关商誉及部分固定资产计提了资产减值，叠加隐形眼 镜渠道建设投入、销售费用增加较多，导致本报告期净利润同比出现较大幅度下降。 ...

Group 1: Company Performance - BeiGene reported a total revenue of 38.205 billion yuan for 2025, a 40.4% increase from 27.214 billion yuan in the previous year, with a net profit of 1.422 billion yuan compared to a loss of 4.978 billion yuan in the prior year [1] - United Imaging achieved a total revenue of 13.821 billion yuan in 2025, reflecting a year-on-year growth of 34.18%, with a net profit of 1.888 billion yuan, up 49.6% [2] - Innovent Biologics expects a profit increase of 80%-94% to between 1.3 billion and 1.4 billion yuan for 2025, with total revenue projected at approximately 7.7-7.8 billion yuan, a growth of 16.0%-17.6% [3] - Zai Lab reported a total revenue of $460 million for 2025, a 15% increase, with significant growth in product sales driven by the performance of its drugs [4] Group 2: Product and Market Developments - BeiGene's global sales of its product, Baiyueze®, reached 28.067 billion yuan, marking a 48.8% year-on-year increase, establishing its leadership in the BTK inhibitor market [1] - United Imaging's growth was attributed to the continuous launch of innovative products and enhanced market recognition of high-end products [2] - Zai Lab's revenue growth was primarily due to increased sales of its products, including significant gains in the fourth quarter [4] - Innovent Biologics noted that revenue growth was driven by increased income from innovative drugs and licensing agreements [3] Group 3: Strategic Moves and Collaborations - Hengrui Medicine signed an exclusive licensing and equity cooperation agreement with Solstice Oncology, with a total transaction value exceeding $1.2 billion [6] - Aibo Medical plans to acquire a 68.31% stake in Demei Medical for 683 million yuan, aiming to expand into the sports medicine sector [7] - The target company in the acquisition has 276 patented technologies and is recognized as a leading enterprise in the domestic sports medicine field [8]

格隆汇2月27日｜有投资者在互动平台向爱博医疗提问：咱们公司和银河通用是一种什么合作关系？仅 仅是购买或者租用银河通用的机器人吗？爱博医疗回复称，公司与银河通用已签订正式合作协议，聚焦 具身智能技术与医疗健康零售场景的深度融合，共同打造24小时隐形眼镜智慧门店，探索智能化医疗零 售新模式。 ...

原有业务陷入增长瓶颈，爱博医疗（688050.SH）向外拓展寻求突破。 2月25日晚间，爱博医疗发布收购计划，拟使用并购贷款及自有资金，作价6.83亿元收购德美联合（重 庆）医疗科技有限公司（以下简称"德美医疗"）68.31%股权。交易完成后，德美医疗将成为爱博医疗的 控股子公司。 据了解，德美医疗是国内运动医学的头部企业。通过此次收购，爱博医疗将从眼科医疗器械领域拓展至 运动医学领域，培育新的盈利增长点。 数据显示，2025年前三季度，爱博医疗实现营业收入11.44亿元，同比增长6.43%；归母净利润和扣非净 利润分别为2.9亿元、2.8亿元，同比下降8.64%、8.14%，明显出现增收不增利的现象。 长江商报记者注意到，本次交易中，德美医疗整体估值达10.74亿元，评估增值率343.29%。交易完成之 后，爱博医疗预计将新增5亿元商誉。 尽管德美医疗的创始股东作出未来三年净利润累计不低于1.65亿元的业绩承诺，但如果未来德美医疗业 绩不及预期，爱博医疗仍将存在商誉减值的风险。 此外，本次交易对价的70%至80%均由爱博医疗以贷款方式筹得，预计将使公司合并报表层面新增一定 规模的有息负债，未来的财务负担亦不 ...

眼科器械龙头爱博医疗拟通过并购切入运动医学领域。在前次披露投资意向一个月后，爱博医疗于2月 26日发布具体收购方案，拟以6.83亿元收购德美联合（重庆）医疗科技有限公司（以下简称"德美医 疗"）68.31%股权，交易作价较净资产账面值溢价超3倍。 爱博医疗最新公告显示，在支付第一期股转款后，本次交易涉及的德美医疗股权将全部完成办理工商变 更登记，爱博医疗将享有作为目标公司股东的全部权利和权益，德美医疗将成为公司控股子公司，纳入 公司合并报表范围。 公告显示，德美医疗为国内运动医学领域头部企业之一，核心产品涵盖全缝线锚钉、界面螺钉、超强缝 线、刨削刀头、关节镜套管、4K超精准摄像系统、可调节支具等。其中，运动医学植入物为主要收入 来源，占营收的比重约80%。 爱博医疗方面表示，通过本次收购标的公司控股权，拟拓宽医疗健康领域布局，在研发、生产制造、销 售渠道等方面与标的公司协同，进一步提升公司业绩与股东回报水平。 针对此次交易的支付方式，爱博医疗方面提到，本次交易对价以现金方式支付，将导致公司产生一定规 模的现金净流出。交易资金部分拟来源于银行并购贷款，贷款比例预计为交易价格的70%—80%，预计 将使公司合并报 ...

Core Viewpoint - Aibo Medical announced plans to acquire a 68.31% stake in Demei Medical for 683 million yuan, which will make Demei a subsidiary and included in Aibo's financial statements [1][2]. Group 1: Acquisition Details - The acquisition price for the 68.31% stake in Demei Medical is 683 million yuan [1]. - Demei Medical, established in 2016, is a leading company in the domestic sports medicine sector with a sales network covering Southeast Asia, Latin America, the Middle East, and Europe [2]. - Demei Medical has won bids for several products in the fourth batch of national high-value consumables procurement, indicating a strong market presence [2]. Group 2: Financial Performance - Demei Medical's projected revenues for 2024 and 2025 are 236 million yuan and 286 million yuan, respectively, with adjusted net profits of 9.29 million yuan and 23.60 million yuan [2]. - The overall gross margin for Demei Medical is approximately 70% [2]. - Demei Medical's net asset book value is 242 million yuan, with a valuation of 1.074 billion yuan, resulting in a value increase rate of 343.29% [6]. Group 3: Strategic Intent and Risks - Aibo Medical aims to leverage its existing R&D advantages and management systems to cultivate new profit growth in the high-potential sports medicine sector [6]. - The acquisition includes performance guarantees, requiring Demei Medical to achieve audited net profits of at least 45 million yuan, 55 million yuan, and 65 million yuan for the years 2026 to 2028, or a cumulative net profit of no less than 165 million yuan [6]. - Aibo Medical's financial strategy for the acquisition involves using a combination of acquisition loans and its own funds, with loans expected to cover 70%-80% of the transaction price [6]. Group 4: Market Context and Challenges - Aibo Medical's recent financial performance has been affected by industry policies such as medical insurance cost control and competitive pressures, leading to declining revenue growth rates [9][11]. - The company reported revenues of 1.41 billion yuan and 1.14 billion yuan for the first three quarters of 2024 and 2025, respectively, with net profits showing a downward trend [9]. - The competitive landscape in the contact lens market is intensifying, with signs of price wars emerging [11].

2月25日，爱博诺德（北京）医疗科技股份有限公司（简称"爱博医疗"）正式宣告跨界切入运动医学赛 道。公告显示，爱博医疗拟以6.83亿元对价，使用并购贷款及自有资金收购德美联合（重庆）医疗科技 有限公司（简称"德美医疗"）68.31%股权。 挑战与机遇并存 对于爱博医疗而言，控股德美医疗既是跨界突围的重要一步，也面临着多重挑战。从行业竞争来看，运 动医学赛道虽潜力巨大，但竞争已日趋激烈，除了施乐辉、强生等外资龙头占据较高市场份额外，国内 也涌现出天星医疗、杭州锐健等优秀企业，德美医疗虽位列国产前三，但要实现进一步突破，仍需持续 的研发投入和市场推广支持。 从自身业务来看，爱博医疗的眼科主业仍需持续发力。为应对集采冲击，爱博医疗在2025年推出了两款 新产品，其中，用于成年人近视矫正的有晶体眼人工晶状体"龙晶PR"目前仍处于市场推广阶段；角膜 塑形镜业务虽呈现回暖态势，2025年第三季度实现双位数增长，但仍难以完全抵消人工晶状体业务的利 润下滑压力。 此次股权收购，双方还设定了业绩承诺，2026年至2028年，德美医疗年度净利润分别不低于4500万元、 5500万元、6500万元，三年累计不低于1.65亿元，若未 ...